![Matthew Hammond](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Matthew Hammond
Fondateur chez
RESEARCH ALLIANCE CORP. II
Profil
Matthew Hammond is the founder of Therapeutics Acquisition Corp., founded in 2020, where the title held was Chief Financial Officer, Secretary & Director from 2020 to 2021.
Dr. Hammond is the founder of Research Alliance Corp.
II, founded in 2020, holding the titles of Director & Chief Investment Officer since 2020.
Current jobs include Chief Executive Officer & Director at Research Alliance Corp.
III starting in 2026, Chief Executive Officer & Director at Research Alliance Corp.
IV starting in 2026, Chief Financial Officer & Director at Indefinite Integral, Inc., Director at Cerebral Therapeutics, Inc., Director at Kira Pharmaceuticals (US) LLC, Director at Ambros Therapeutics, Inc. starting in 2025, Principal at RA Capital Management LP (Private Equity) since 2014, and Partner at RA Capital Management LP since 2024.
Former jobs include Director at DTx Pharma, Inc. from 2021 to 2023, Director at Jnana Therapeutics, Inc. from 2021 to 2024, Director at Forge Biologics, Inc. from 2021 to 2023, and Member-Supervisory Board at Emergence Therapeutics AG from 2022 to 2023.
Education history includes an MBA and a doctorate from the University of Connecticut, both conferred in 2014, and an undergraduate degree from the University of Georgia conferred in 2010.
Postes actifs de Matthew Hammond
| Sociétés | Poste | Début |
|---|---|---|
| RESEARCH ALLIANCE CORP. II | Fondateur | 17/07/2020 |
RA Capital Management LP
 RA Capital Management LP Investment ManagersFinance RA Capital is a multi-stage investment manager that focuses evidence-based investing in public and private healthcare and life science companies which develops drugs, medical devices, diagnostics, services, and research tools. The firm’s portfolio of private and public companies spans the globe and most therapeutic areas across all stages from discovery through commercialization. | Analyst-Equity | 01/12/2014 |
RA Capital Management LP (Private Equity)
 RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of healthcare and life sciences. It provides financing for pre-seed, seed stage, early stage and growth capital requirements . The firm acts as a lead and co-investor, makes follow-on investments and has a board seat requirement. | Private Equity Investor | 01/12/2014 |
Cerebral Therapeutics, Inc.
 Cerebral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Develops neurological therapeutics for uncontrolled neurological diseases | Directeur/Membre du Conseil | - |
Indefinite Integral, Inc.
 Indefinite Integral, Inc. Financial ConglomeratesFinance Provides financial services | Directeur Financier/CFO | - |
Kira Pharmaceuticals (US) LLC
 Kira Pharmaceuticals (US) LLC Pharmaceuticals: MajorHealth Technology Develops transformative therapies for people with complement-mediated diseases | Directeur/Membre du Conseil | - |
Anciens postes connus de Matthew Hammond
| Sociétés | Poste | Fin |
|---|---|---|
Jnana Therapeutics, Inc.
 Jnana Therapeutics, Inc. BiotechnologyHealth Technology Operates as a chemo proteomics platform to develop small molecule medicines | Directeur/Membre du Conseil | 01/09/2024 |
Forge Biologics, Inc.
 Forge Biologics, Inc. BiotechnologyHealth Technology Operates as a hybrid gene therapy contract manufacturing and clinical-stage therapeutics development company | Directeur/Membre du Conseil | 01/12/2023 |
Emergence Therapeutics AG
 Emergence Therapeutics AG Pharmaceuticals: MajorHealth Technology Operates as biopharmaceutical company which develops novel antibody drugs | Directeur/Membre du Conseil | 01/08/2023 |
| ░░░ ░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░ | ░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Matthew Hammond
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
81
Relations au 1er degré
13
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 13 |
|---|---|
RA Capital Management LP
RA Capital Management LP Investment ManagersFinance RA Capital is a multi-stage investment manager that focuses evidence-based investing in public and private healthcare and life science companies which develops drugs, medical devices, diagnostics, services, and research tools. The firm’s portfolio of private and public companies spans the globe and most therapeutic areas across all stages from discovery through commercialization. | Finance |
University of Connecticut
 University of Connecticut Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Georgia
 University of Georgia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
DTx Pharma, Inc.
 DTx Pharma, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops siRNA therapies for neuroscience indications | Health Technology |
Jnana Therapeutics, Inc.
Jnana Therapeutics, Inc. BiotechnologyHealth Technology Operates as a chemo proteomics platform to develop small molecule medicines | Health Technology |
Indefinite Integral, Inc.
Indefinite Integral, Inc. Financial ConglomeratesFinance Provides financial services | Finance |
Cerebral Therapeutics, Inc.
Cerebral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Develops neurological therapeutics for uncontrolled neurological diseases | Commercial Services |
RA Capital Management LP (Private Equity)
RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of healthcare and life sciences. It provides financing for pre-seed, seed stage, early stage and growth capital requirements . The firm acts as a lead and co-investor, makes follow-on investments and has a board seat requirement. | Finance |
Emergence Therapeutics AG
Emergence Therapeutics AG Pharmaceuticals: MajorHealth Technology Operates as biopharmaceutical company which develops novel antibody drugs | Health Technology |
Therapeutics Acquisition Corp.
 Therapeutics Acquisition Corp. Financial ConglomeratesFinance Operates as a blank check company | Finance |
Forge Biologics, Inc.
Forge Biologics, Inc. BiotechnologyHealth Technology Operates as a hybrid gene therapy contract manufacturing and clinical-stage therapeutics development company | Health Technology |
Kira Pharmaceuticals (US) LLC
Kira Pharmaceuticals (US) LLC Pharmaceuticals: MajorHealth Technology Develops transformative therapies for people with complement-mediated diseases | Health Technology |
Research Alliance Corp. II
 Research Alliance Corp. II Financial ConglomeratesFinance Operates as a blank check company | Finance |
Choisissez Zonebourse 
